Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtre
1.
Tuberculosis and Respiratory Diseases ; : 231-233, 2012.
Article Dans Anglais | WPRIM | ID: wpr-148474

Résumé

Tadalafil is a phosphodiesterase-5 inhibitor (PDE5I), which is widely used to treat erectile dysfunction. Although PDE5Is have excellent safety profiles, and most of the side effects are mild, rare serious adverse events have been reported in association with PDE5Is. Thrombosis is one of those events, and a few previous reports have suggested the association of PDE5Is with thrombosis. We report the case of a 61-year-old male who developed pulmonary embolism combined with pulmonary infarction directly after taking tadalafil. Both the patient and the physician suspected tadalafil as the culprit drug, as the patient was in an otherwise healthy condition. However, after extensive evaluation, we noticed that factor VIII levels were elevated. Prior reports suggesting the association between thrombosis and PDEIs either lack complete information on coagulation factors, or show inconsistencies in their results. Physicians should operate caution prior to accepting the diagnosis of adverse drug reaction.


Sujets)
Humains , Mâle , Adulte d'âge moyen , Facteurs de la coagulation sanguine , Carbolines , Cyclic Nucleotide Phosphodiesterases, Type 5 , Effets secondaires indésirables des médicaments , Dysfonctionnement érectile , Facteur VIII , Inhibiteurs de la phosphodiestérase-5 , Embolie pulmonaire , Infarctus pulmonaire , Thrombose , Tadalafil
SÉLECTION CITATIONS
Détails de la recherche